OBI-905 (HER2 Targeted ADC)

OBI-905 is an antibody-drug conjugate (ADC) comprising a monoclonal antibody specific to HER2 (human epidermal growth factor receptor 2), linked to a potent topoisomerase I inhibitor payload through OBI’s proprietary GlycOBI^TM platform, resulting in a novel and potential best-in-class ADC designed to HER2 relevant cancer types.

Overexpression of HER2 is evident in several types of cancers, notably breast and gastric cancers, which tend to exhibit more aggressive behavior and a higher risk of recurrence.OBI-905 enables the direct delivery of potent cytotoxic agent to HER2-positive cancer cells and effectively eliminating the targeted cells, minimizing potential harm to surrounding healthy tissues to reduce side effects. The effectiveness of HER2-ADC has been demonstrated in later lines of therapy for metastatic HER2-positive breast cancer.